Literature DB >> 2142674

Immunomodulatory properties of platelet factor 4: prevention of concanavalin A suppressor-induction in vitro and augmentation of an antigen-specific delayed-type hypersensitivity response in vivo.

E O Gregg1, L Yarwood, M J Wagstaffe, D S Pepper, M C Macdonald.   

Abstract

The immunomodulatory properties of platelet factor 4 (PF4) have been examined in vitro and in vivo. This agent prevented the induction of concanavalin A (Con A)-induced suppressor cells in vitro in a dose-dependent manner but it did not affect the function of established Con A suppressor cells. This effect was not due to an enhanced production of interleukin-2 (IL-2) by lymphocytes exposed to PF4. The delayed-type hypersensitivity (DTH) reaction to sheep erythrocytes (SRBC) was used as a model for the generation of antigen-specific suppression in vivo. PF4 enhanced the magnitude of the swelling following SRBC challenge 10 days after sensitization by the i.p. route or following sensitization by both the s.c. and i.p. routes. These studies show that PF4 has immunomodulatory activities in well-defined models of cell-mediated immunity and suggest that this agent has a potential use in the dissection of events in antigen-specific suppression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142674      PMCID: PMC1384198     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  14 in total

1.  Regulation of delayed-type hypersensitivity. I. T suppressor cells for delayed-type hypersensitivity to sheep erythrocytes in mice.

Authors:  F Y Liew
Journal:  Eur J Immunol       Date:  1977-10       Impact factor: 5.532

2.  Immunologic suppression after oral administration of antigen. III. Activation of suppressor-inducer cells in the Peyer's patches.

Authors:  J A Mattingly
Journal:  Cell Immunol       Date:  1984-06       Impact factor: 4.868

3.  Heterogeneity of human suppressor cells induced by concanavalin A as determined in simultaneous assays of immune function.

Authors:  H B Herscowitz; T Sakane; A D Steinberg; I Green
Journal:  J Immunol       Date:  1980-03       Impact factor: 5.422

4.  Platelet factor 4 is chemotactic for neutrophils and monocytes.

Authors:  T F Deuel; R M Senior; D Chang; G L Griffin; R L Heinrikson; E T Kaiser
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

5.  Platelet factor 4 regulates osteoclastic bone resorption in vitro.

Authors:  J E Horton; J Harper; E Harper
Journal:  Biochim Biophys Acta       Date:  1980-07-03

6.  The expression in Escherichia coli of recombinant human platelet factor 4, a protein with immunoregulatory activity.

Authors:  A D Barone; J Ghrayeb; U Hammerling; M B Zucker; G J Thorbecke
Journal:  J Biol Chem       Date:  1988-06-25       Impact factor: 5.157

7.  Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.

Authors:  E O Gregg; I C Gregg; I Green
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

8.  Reversal of Con A-induced suppression by a platelet-derived factor which binds to activated suppressor T cells.

Authors:  I R Katz; M K Bell; M K Hoffman; G J Thorbecke
Journal:  Cell Immunol       Date:  1986-06       Impact factor: 4.868

9.  T cell growth factor abrogates concanavalin A-induced suppressor cell function.

Authors:  R Palacios; G Möller
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

10.  Inhibitory and stimulatory effects of concanavalin A on the response of mouse spleen cell suspensions to antigen. I. Characterization of the inhibitory cell activity.

Authors:  R W Dutton
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  1 in total

1.  The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation.

Authors:  A D Luster; S M Greenberg; P Leder
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.